Pharma Journalist -

Adagene Inc. has announced an amendment to its 2021 collaboration and license agreement with Exelixis, allowing Exelixis to use Adagene’s SAFEbody technology to create a third masked…
Read More...

Reunion Neuroscience, a clinical-stage biopharmaceutical company focused on next-generation psychedelic-inspired therapies for mental health, announced the final closing of its Series A…
Read More...

VarmX, a biotech company specializing in treatments for patients on direct oral anticoagulants targeting activated factor Xa (FXa DOACs), has entered a strategic collaboration with…
Read More...

Raludotatug deruxtecan (R-DXd), a novel CDH6-targeted antibody-drug conjugate developed by Daiichi Sankyo and Merck, has received Breakthrough Therapy Designation (BTD) from the U.S.…
Read More...

Akeso Inc. announced that its monoclonal antibody ligufalimab (AK117), targeting CD47, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration for the…
Read More...

Cadrenal Therapeutics, Inc., a biopharmaceutical company focused on innovative anticoagulation therapies, has announced the acquisition of eXIthera Pharmaceuticals’ portfolio of Factor…
Read More...

aTyr Pharma, Inc. a clinical-stage biotech company developing first-in-class therapeutics from its proprietary tRNA synthetase platform, today announced topline results from its Phase 3…
Read More...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the label of Novo Nordisk’s oral diabetes drug Rybelsus (oral…
Read More...

Amneal Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for sodium oxybate oral solution 500 mg/mL, a…
Read More...

Boston, MA (September 22, 2025) & Washington, D.C. (November 6, 2025). The LEAN Cell & Gene Summit series, co-organised by ScaleReady, and Hanson Wade, is proud to unveil its…
Read More...